Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A2 | O95436 | 1/20 | 0.56 |
| ▸ | SMYD2 | Q9NRG4 | 5/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | BRAF | P15056 | 5/20 | 0.34 |
| ▸ | RAF1 | P04049 | 3/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15432739 | 0.90 | SLC34A2 (0.60) | SLC34A2SMYD2HTR2ABRAFRAF1 | |
| SCHEMBL16355206 | 0.90 | SLC34A2 (0.59) | SLC34A2SMYD2HTR2ABRAFRAF1 | |
| SCHEMBL15432752 | 0.86 | SLC34A2 (0.63) | SLC34A2KITFLT3BRAFRAF1 | |
| SCHEMBL16355209 | 0.85 | SLC34A2 (0.62) | SLC34A2BRAFRAF1GPR52 | |
| SCHEMBL19580025 | 0.85 | SLC34A2 (0.75) | SLC34A2BRAFRAF1 | |
| SCHEMBL15432736 | 0.85 | SLC34A2 (0.75) | SLC34A2BRAFRAF1 | |
| SCHEMBL46437 | 0.85 | SLC34A2 (0.60) | SLC34A2KITFLT3BRAFRAF1 | |
| SCHEMBL15432744 | 0.84 | SLC34A2 (0.65) | SLC34A2BRAFRAF1GPR52 | |
| SCHEMBL19580017 | 0.84 | SLC34A2 (0.57) | SLC34A2BRAFRAF1GPR52 | |
| SCHEMBL19579940 | 0.84 | SLC34A2 (0.58) | SLC34A2BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC10A2, SLC34A2, SLC34A3 | SLC34A2 2/4885SMYD2 4638/4885KIT 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.